The global pharma industry experienced 0.48% rise in social media posts on microbiome in Q1 2023 compared with the previous quarter, with the highest share accounted for Viome, according to GlobalData’s analysis of social media posts. GlobalData’s Microbiome-Targeting Therapeutics in Infectious Diseases – Thematic Research report provides information on market classification by therapy and technologies, regulatory and market access details for live biotherapeutic products (LBP) in the US and 5EU, and product & company profiles. It helps identify which indications are the mo Buy the report here.

Smarter leaders trust GlobalData

Notably, Covid-19 was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions ahead of orphan designated drugs and innovation, according to GlobalData.

Of the 50 leading companies in the pharma industry, Viome had the most mentions of microbiome in Q1 2023. GlobalData identified 3,146 microbiome-related posts in the industry's social media activity - 0.2% of all posts - and an increase of 0.48% in Q1 2023 compared with Q4 2022.

For further understanding of GlobalData's Microbiome-Targeting Therapeutics in Infectious Diseases – Thematic Research buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.